Safety And Efficacy Of Antipsychotics In Schizophrenic Patients Visiting A Tertiary Care Teaching Hospital In Warangal: A Comparative Study
Keywords:
Risperidone, Olanzapine, Amisulpride, Lurasidone, Aripiprazole, SchizophreniaAbstract
The objective of present study is to compare the safety and efficacy of Antipsychotics in Schizophrenic patients by using Simpson Angus Score (SAS) and Positive and Negative Syndrome Score (PANSS).
Method: It is a Prospective, observational comparative multicentric study conducted in patients diagnosed with Schizophrenia in Warangal, Telangana state. The study protocol, Data collection sheet were submitted. A total of 513 patients were screened for the study prescribed with Risperidone, Olanzapine, Amisulpride, Lurasidone, Aripiprazole.
Statistical Analysis: All the parameters were expressed as graphs and data analysis was performed using MS EXCEL and Graph pad prism 9.2.0 Version. Paired t test was computed for study variables.
Results: The results were confirmed by comparing the safety and efficacy of antipsychotics (Risperidone, Olanzapine, Amisulpride, Lurasidone, Aripiprazole) by using PANSS and SAS scale. Efficacy in reducing Positive and Negative symptoms severity was slightly high in Lurasidone and Aripiprazole than compared to Olanzapine, Risperidone, Amisulpride. Safety of Lurasidone and Aripiprazole was slightly more compared to Olanzapine, Risperidone and Amisulpride.
Downloads
References
Stephen Stahl M. Stahl’s Essential Psychopharmacology: Neurospecific Basis and PracticalApplication. 4th ed. New York: Cambridge University Press; 2013. 80-120.
Ahuja N. A short textbook of psychiatry. 7th ed. New Delhi, India: Jaypee Brothers Medical;2010.55-65.
Anthony Lehman F, Chair Jeffrey Lieberman A, Lisa Dixon B, ThomasMcGlashan V, Alexander Miller L, Diana Perkins O, Julie Kreyenbuhl. Practice Guidelines for the Treatment of patients with Schizophrenia. 2nd ed. 2004. 9-40.
Cheng Z, Yuan Y, Han X, Yang L, Cai S, Yang F et al. An open-label comparisonof aripiprazole, olanzapine and risperidone for the acute treatment of first-episodeschizophrenia:Eightweekoutcomes of Psychopharmacology. 2019; 33(10): 1227-1236.
Higuchi T, Ishigooka J, Iyo M, Hagi K. Safety and effectiveness of lurasidone for the treatment of schizophrenia: Results of a 26‐week open‐label extension study. Asia Pacific Psychiatry. 2019;12(1).
Jindal K, Singh G, Munjal V. Aripiprazole versus olanzapine in the treatment of schizophrenia: A clinical study from India. International Journal ofPsychiatry in Clinical Practice. 2012;17(1):21-29.
Citrome L, Weiden P, McEvoy J, Correll C, Cucchiaro J, Hsu J et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectrums. 2013;19(4):330-339.
Meltzer H, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J et al. Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study. American Journal of Psychiatry2011;168(9):957-967.
Potkin S, Saha A, Kujawa M, Carson W, Ali M, Stock E et al. Aripiprazole, an Antipsychotic with a Novel Mechanism of Action, and Risperidone vs Placebo in Patients with Schizophrenia and Schizoaffective Disorder. Archives of General Psychiatry. 2003;60(7):681.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
